Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra Low Dose Decitabine in MDS
NCT02779569Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of decitabine in myelodysplastic syndrome (MDS) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Grade III and IV hematologic toxicity at 8 months. Status: unknown.
02
Drugs
decitabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02779569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02779569.